Stockscreener 앱 받기
9.70
3.30%
0.31
시간 외 거래:
9.69
-0.010
-0.10%
전일 마감가:
$9.39
열려 있는:
$9.38
하루 거래량:
18.39M
Relative Volume:
1.48
시가총액:
$11.38B
수익:
$14.33B
순이익/손실:
$-3.79B
주가수익비율:
-3.0599
EPS:
-3.17
순현금흐름:
$1.84B
1주 성능:
+10.10%
1개월 성능:
+4.75%
6개월 성능:
-9.60%
1년 성능:
-19.83%
1일 변동 폭
$9.2501
$9.73
1주일 범위
$8.735
$9.73
52주 변동 폭
$6.85
$13.55
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
VTRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
9.70 | 10.27B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
147.35 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.54 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.37 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.50 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Viatris Earnings Call: Growth Amid Challenges - The Globe and Mail
Viatris aims for top-half 2025 revenue and EPS guidance while advancing late-stage pipeline - MSN
Research Alert: CFRA Keeps Sell Opinion On Shares Of Viatris Inc. - 富途牛牛
Goldman Sachs Adjusts Price Target on Viatris to $11 From $10, Maintains Neutral Rating - MarketScreener
Will Viatris’ (VTRS) Leadership Moves and Steady Outlook Signal Resilience or Ongoing Transition? - simplywall.st
Viatris Inc. (NASDAQ:VTRS) Q2 2025 Earnings Call Transcript - Insider Monkey
Viatris: Q2 Earnings Snapshot - Connecticut Post
Viatris To Seek FDA Approval For MR-141 In Presbyopia In 2H, 2025Did The Stock Catch Your Eye? - RTTNews
Viatris Inc (VTRS) Q2 2025 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges By GuruFocus - Investing.com Canada
Viatris Reports Mixed Q2 Earnings Amid Pipeline Progress and Operational Challenges - AInvest
Viatris Inc. Reports Strong Q2 2025 Results - TipRanks
Viatris 2025 Q2 Earnings Narrowed Losses Amid Revenue Decline - AInvest
Research Alert: Viatris Reports Q2 Top And Bottom-line Beats - 富途牛牛
Viatris Inc. (VTRS) Stock Forecasts - Yahoo Finance
Viatris Earnings: Solid Results Lift Shares, but We Think There Is a Lot More Upward Momentum Left - Morningstar
Divestitures Muddy Viatris' 2025, but New Launches and Pipeline Support Our Outlook - Morningstar
Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise - whbl.com
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris' Investment Prospects: Navigating Business Model Concerns and Analyst Expectations - AInvest
Viatris (NASDAQ:VTRS) Beats Q2 Sales Targets, Stock Soars - TradingView
Earnings call transcript: Viatris beats Q2 2025 estimates, stock rises - Investing.com
Earnings call transcript: Viatris beats Q2 2025 estimates, stock rises By Investing.com - Investing.com Canada
Viatris Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Postoperative Pain Management Market Poised for Transformation During the Forecast Period (2025–2034) with Rising Non-Opioid Adoption | DelveInsight - GlobeNewswire Inc.
Viatris Inc. shares rise 5.20% intraday after beating quarterly profit and revenue estimates. - AInvest
Viatris Q2 Earnings & Revenues Beat Estimates, Shares Rise - AInvest
Viatris Expects Mid-2025 Revenue and EPS Guidance, Advances Late-Stage Pipeline - AInvest
Viatris (VTRS) Q2 2025 Earnings: Navigating Regulatory Challenges and Strategic Shareholder Returns - AInvest
Viatris Q2 2025: Unraveling Contradictions in Tariffs, Growth Strategies, and Market Opportunities - AInvest
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates - TradingView
Viatris Outpaces Expectations Despite India Facility Setback - Finimize
Viatris' Q2 2025 Outperformance: A Case Study in Resilience and Strategic Execution - AInvest
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Viatris, Ralph Lauren, Kontoor Brands - TradingView
Australia's V2Food Acquires US-Based Daring Foods, Partners with Ajinomoto for Clean-Protein Products - AInvest
Viatris Surpasses Q2 2025 Revenue Expectations - TipRanks
Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Viatris Q2 Adjusted Earnings, Revenue Fall - MarketScreener
Viatris in charts: Q2 sees sequential growth across product categories and regions - Seeking Alpha
Viatris Q2 2025 slides: reaffirms guidance despite Indore challenges By Investing.com - Investing.com Canada
Viatris Q2 2025 slides: reaffirms guidance despite Indore challenges - Investing.com
Viatris Q2 Earnings Performance: A Turning Point Amidst Sector-Wide Headwinds? - AInvest
Viatris' Resilience and Shareholder Returns: A Strategic Buy Opportunity Amid Diversified Declines - AInvest
Viatris earnings beat by $0.07, revenue topped estimates - Investing.com Canada
Earnings Flash (VTRS) Viatris Inc. Reports Q2 Revenue $3.58B, vs. FactSet Est of $3.47B - MarketScreener
Earnings Flash (VTRS) Viatris Inc. Posts Q2 Adjusted EPS $0.62 per Share, vs. FactSet Est of $0.56 - MarketScreener
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance - Viatris
Viatris Q2 2025 Results Exceed Expectations, Reiterates 2025 Guidance - AInvest
Thursday Earnings Preview: Viatris, Eli Lilly, ConocoPhillips, Datadog, Warner Bros. Discovery - AInvest
Viatris Inc. Appoints Simmons to Board of Directors to Enhance Leadership and Governance - AInvest
Viatris Launches ‘EmpowerED for Life’ to Tackle Erectile Dysfunction, Advocates Men’s Health in Africa - thisdaylive
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.47%
0.47%
자본화:
|
볼륨(24시간):